This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    25/07/14

    GSK files RTS,S Malaria vaccine at EMA.

    GSK announced that it has submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    06/07/16

    Decline in efficacy of Mosquirix vaccine for malaria after seven years.- GSK

    The world's first malaria vaccine, RTS,S (Mosquirix) developed by GlaxoSmithKline, provides some protection after three doses but its effect declines...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/03/13

    RTS,S Malaria Vaccine (GSK) disappoints

    The effectiveness of a Malaria Vaccine, RTS,S, developed by GlaxoSmithKline wanes over time, with the shot protecting only 16.8 percent...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/04/15

    Final results of Phase III trial of RTS,S Malaria vaccine published in The Lancet-Glaxo Smith Kline

    Final results from a large-scale Phase III trial of RTS,S malaria vaccine candidate, from Glaxo Smith Kline, including the impact...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/12/24

    First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines

    GSK plc  and Medicines for Malaria Venture (MMV) announced  that the World Health Organization (WHO) has awarded prequalification to tafenoquine, the first single-dose medicine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    24/04/24

    Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria.

    Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety

    Journals
    Journal
    26/10/20

    What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

    In this Review, we explore the challenges in assessing the efficacy of candidate SARS-CoV-2 vaccines, discuss the caveats needed to interpret reported efficacy endpoints, and provide insight into answering the seemingly simple question, “Does this COVID-19 vaccine work?”

    • Source: The Lancet Infectious Diseases
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    03/10/23

    R21/Matrix-M Malaria vaccine with Novavax’s adjuvant technology receives WHO Recommendation.

    The World Health Organization (WHO) announced its recommendation of the R21/Matrix-M malaria vaccine to prevent malaria in children following advice from its Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG)

    Journals
    Journal
    01/01/19

    A vaccine against Alzheimer`s disease: anything left but faith?

    Areas covered: We provide an overview of the molecular pathology that leads to an increase in Aβ peptide accumulation, of the mechanism of action for antibody mediated therapies and of the therapeutic vaccines that target...

    • Source: Expert Opinion on Biological Therapy
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    11/11/12

    RTS.S anti malaria vaccine further results in African study

    Results from a pivotal, large-scale Phase III trial, published online in the New England Journal of Medicine, show that the...

    See more